Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...

Please provide your email address to receive an email when new articles are posted on . Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had ...

Paroxysmal nocturnal hemoglobinuria leaves red blood cells more vulnerable to destruction. A common side effect is blood clots, known as thrombosis. This is largely preventable with medication to ...

Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and lethal disorder of the blood in which the body attacks and destroys red blood cells in massive amounts. This focus collection and short ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, potentially life-threatening disorder linked to a specific gene. It can occur at any age but most often is diagnosed in young adults. PNH ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...